Solid Biosciences Statistics
Share Statistics
Solid Biosciences has 77.52M
shares outstanding. The number of shares has increased by 101.91%
in one year.
| Shares Outstanding | 77.52M |
| Shares Change (YoY) | 101.91% |
| Shares Change (QoQ) | 93.95% |
| Owned by Institutions (%) | 89.01% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 113 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 7.09M, so 9.15% of the outstanding
shares have been sold short.
| Short Interest | 7.09M |
| Short % of Shares Out | 9.15% |
| Short % of Float | 10.89% |
| Short Ratio (days to cover) | 5.01 |
Valuation Ratios
The PE ratio is -1.31 and the forward
PE ratio is -1.29.
Solid Biosciences's PEG ratio is
0.04.
| PE Ratio | -1.31 |
| Forward PE | -1.29 |
| PS Ratio | 0 |
| Forward PS | 0.6 |
| PB Ratio | 1.19 |
| P/FCF Ratio | -1.62 |
| PEG Ratio | 0.04 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Solid Biosciences.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.2,
with a Debt / Equity ratio of 0.18.
| Current Ratio | 5.2 |
| Quick Ratio | 5.2 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | -0.2 |
| Debt / FCF | -0.24 |
| Interest Coverage | -381.55 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,246,970 |
| Employee Count | 100 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -63.25% in the
last 52 weeks. The beta is 2.33, so Solid Biosciences's
price volatility has been higher than the market average.
| Beta | 2.33 |
| 52-Week Price Change | -63.25% |
| 50-Day Moving Average | 3.47 |
| 200-Day Moving Average | 5.2 |
| Relative Strength Index (RSI) | 46.39 |
| Average Volume (20 Days) | 1,485,322 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -129.73M |
| Net Income | -124.7M |
| EBITDA | -121.9M |
| EBIT | -125.04M |
| Earnings Per Share (EPS) | -3.06 |
Full Income StatementBalance Sheet
The company has 80.23M in cash and 24.18M in
debt, giving a net cash position of 56.06M.
| Cash & Cash Equivalents | 80.23M |
| Total Debt | 24.18M |
| Net Cash | 56.06M |
| Retained Earnings | -783.45M |
| Total Assets | 343.9M |
| Working Capital | 284.63M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -100.01M
and capital expenditures -654K, giving a free cash flow of -100.67M.
| Operating Cash Flow | -100.01M |
| Capital Expenditures | -654K |
| Free Cash Flow | -100.67M |
| FCF Per Share | -2.47 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
